These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37855029)

  • 21. Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
    Yamashita Y; Morimoto T; Muraoka N; Oyakawa T; Umetsu M; Akamatsu D; Nishimoto Y; Sato Y; Takada T; Jujo K; Minami Y; Ogihara Y; Dohi K; Fujita M; Nishikawa T; Ikeda N; Hashimoto G; Otsui K; Mori K; Sueta D; Tsubata Y; Shoji M; Shikama A; Hosoi Y; Tanabe Y; Chatani R; Tsukahara K; Nakanishi N; Kim K; Ikeda S; Mo M; Yoshikawa Y; Kimura T;
    Circulation; 2023 Nov; 148(21):1665-1676. PubMed ID: 37638968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M
    Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
    Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
    Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
    Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
    Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Riaz IB; Fuentes HE; Naqvi SAA; He H; Sipra QR; Tafur AJ; Padranos L; Wysokinski WE; Marshall AL; Vandvik PO; Montori V; Bryce AH; Liu H; Badgett RG; Murad MH; McBane RD
    Mayo Clin Proc; 2022 Feb; 97(2):308-324. PubMed ID: 34172290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Woodruff S; Lee AYY; Carrier M; Feugère G; Abreu P; Heissler J
    J Thromb Thrombolysis; 2019 May; 47(4):495-504. PubMed ID: 30859370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
    Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
    J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Li A; Manohar PM; Garcia DA; Lyman GH; Steuten LM
    Thromb Res; 2019 Aug; 180():37-42. PubMed ID: 31200341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
    Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
    Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
    McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
    J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
    Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
    J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
    Planquette B; Bertoletti L; Charles-Nelson A; Laporte S; Grange C; Mahé I; Pernod G; Elias A; Couturaud F; Falvo N; Sevestre MA; Ray V; Burnod A; Brebion N; Roy PM; Timar-David M; Aquilanti S; Constans J; Bura-Rivière A; Brisot D; Chatellier G; Sanchez O; Meyer G; Girard P; Mismetti P;
    Chest; 2022 Mar; 161(3):781-790. PubMed ID: 34627853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
    Hakoum MB; Kahale LA; Tsolakian IG; Matar CF; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006649. PubMed ID: 29363105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study.
    Chatani R; Yamashita Y; Morimoto T; Muraoka N; Umetsu M; Nishimoto Y; Takada T; Ogihara Y; Nishikawa T; Ikeda N; Otsui K; Sueta D; Tsubata Y; Shoji M; Shikama A; Hosoi Y; Tanabe Y; Tsukahara K; Nakanishi N; Kim K; Ikeda S; Mushiake K; Kadota K; Ono K; Kimura T
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):422-431. PubMed ID: 38650055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.